Effect of the antitumor drug lonidamine on glucose metabolism of adriamycin-sensitive and -resistant human breast cancer cells

Oncology Research

Volumn 8, Issue 3, 1996, Pages 111-120

  Fanciulli, Maurizio ^a   Valentini, Alessandra ^a   Bruno, Tiziana ^a   Citro, Gennaro ^a   Zupi, Gabriella ^a   Floridi, Aristide ^a,b  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

glucose metabolism; lonidamine; MCF 7 cells; mitochondrial hexokinase; multidrug resistance

Indexed keywords

ADENOSINE PHOSPHATE; ANTINEOPLASTIC AGENT; DOXORUBICIN; GLUCOSE; HEXOKINASE; LONIDAMINE;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; DRUG ACCUMULATION; DRUG EFFICACY; GLUCOSE METABOLISM; GLUCOSE UTILIZATION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL;

EID: 0029952517     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. 1. Curt, G. A.; Clendennin, N. J.; Chabner, B. A. Drug resistance in cancer. Cancer Treat. Rep. 68:87-99; 1984.
2. 2. Beck, W. T. The cell biology of multiple drug resistance. Biochem. Pharmacol. 36:2879-2887; 1987.
3. 3. Bradley, G.; Juranka, P. F.; Ling, V. Mechanism of multidrug resistance. Biochem. Biophys. Acta 948:87-128; 1988.
4. 4. Van der Bliek, A. M.; Borst, P. Multidrug resistance. Adv. Cancer Res. 52:165-203; 1989.
5. 5. Master, J. R. W. Biochemical basis of resistance to chemotherapy. Radiother. Oncol. 19:297-305; 1990.
6. 6. Myers, C.; Cowan, K.; Sinha, B.; Chabner, B. The phenomenon of pleiotropic drug resistance. In: De Vita, V. T.; Hellman, S.; Rosenberg, S. A., eds. Important advances in oncology. Philadelphia: J. B. Lippincott; 1987:pp. 27-38.
7. 7. Hayes, J. D.; Wolfm, C. R. Molecular mechanisms of drug resistance. Biochem. J. 272:281-295; 1990.
8. 8. Robinson, I. B. The molecular mechanism of multidrug resistance in tumor cells. J. Clin. Physiol. Biochem. 5:140-151; 1987.
9. 9. Schinkel, A. H.; Borst, P. Multidrug resistance mediated by P-glycoprotein. Semin. Cancer Biol. 2:213-226; 1991.
10. 10. Kartner, N.; Riordan, J. R.; Ling, V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 221:1285-1288; 1983.
11. 11. Gottesman, M. M.; Pastan, I. The multidrug transporter, a double-edged sword. J. Biol. Chem. 263:12163-12166; 1988.
12. 12. Lankelma, J.; Spoelstra, E. C.; Dekker, H.; Broxterman, H. J. Evidence for daunomycin efflux from multidrug-resistant 2780 AD human ovarian carcinoma cells against a concentration gradient. Biochem. Biophys. Acta 1055:217-222; 1990.
13. 13. Lyon, R. C.; Cohen, J. S.; Faustino, P. J.; Megnin, F.; Myers, C. E. Glucose metabolism in drug-sensitive and drug-resistant human breast cancer cells monitored by magnetic resonance spectroscopy. Cancer Res. 48: 870-877; 1988.
14. 14. Fanciulli, M.; Bruno, T.; Castiglione, S.; Del Carlo, C.; Paggi, M. G.; Floridi, A. Glucose metabolism in adriamycin-sensitive and -resistant LoVo human colon carcinoma cells. Oncol. Res. 5:357-362; 1993.
15. 15. Floridi, A.; Paggi, M. G.; Marcante, M. L.; Silvestrini, B.; Caputo, A.; De Martino, C. Lonidamine, a selective inhibitor of aerobic murine tumor cells. J. Natl. Cancer Inst. 66:497-499; 1981.
16. 16. Floridi, A.; Paggi, M. G.; D'Atri, S.; De Martino, C.; Marcante, M. L.; Silvestrini, B.; Caputo, A. Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells. Cancer Res. 41:4661-4666; 1981.
17. 17. Floridi, A.; Lehninger, A. L. Action of the antitumor and antispermatogenic agent lonidamine on electron transport in Ehrlich ascites tumor mitochondria. Arch. Biochem. Biophys. 266:73-83; 1983.
18. 18. Pedersen, P. L. Tumor mitochondria and the bioenergetics of cancer cells. Prog. Exp. Tumor Res. 22:190-274; 1978.
19. 19. Malorni, W.; Arancia, G.; De Martino, C.; Nista, A.; Accinni, L.; Masella, R.; Cantafora, A. On the mechanism of action of lonidamine: a study on human erythrocyte membrane. Exp. Mol. Pathol. 49:361-372; 1988.
20. 20. Santini, M. T.; Cametti, C.; Indovina, P. L.; Malorni, W.; Benassi, M.; Gentile, F. P.; Castiglione, S.; Floridi, A. Effects of Lonidamine on the membrane electrical properties of Ehrlich ascites tumor cells. FEBS Lett. 291: 196-172; 1991.
21. +, mitochondrial and cell membrane structure. J. Exp. Clin. Cancer Res. 10:1-15; 1991.
22. 22. Paggi, M. G.; Floridi, A.; De Martino, C.; Nista, A.; Marcante, M. L.; Caputo, A.; Silvestrini, B. Inhibition of lactate production by lonidamine in human tumors. In: Periti, P.; Grassi, G. G., eds. Current chemotherapy and immunotherapy: proceedings of the 12th International Congress of Chemotherapy, Florence, Italy, 19-24 July, 1981. Washington, DC: American Society for Microbiology; 1982:pp. 1344-1345.
23. 23. Raaphorst, G. P.; Feeley, M. M.; Heller, D. P.; Danjoux, C. E.; Martin, L.; Maroun, J. A.; De Santis, A. J. Lonidamine can enhance the cytotoxic effect of cisplatin in human tumor cells and in rodent cells. Anticancer Res. 10:923-928; 1990.
24. 24. Floridi, A.; Gentile, F. P.; Bruno, T.; Fanciulli, M.; Paggi, M. G.; Zeuli, M.; Benassi, M. Cytotoxic effect of the association of BCNU with rhein or lonidamine on a human glioma cell line. Anticancer Res. 11:789-792; 1991.
25. 25. Floridi, A.; Gambacurta, A.; Bagnato, A.; Bianchi, C.; Paggi, M. G.; Silvestrini, B.; Caputo, A. Modulation of adriamycin uptake by lonidamine in Ehrlich ascites tumor cells. Exp. Mol. Pathol. 49:421-431; 1988.
26. 26. Rosbe, K. W.; Brann, T. W.; Holden, S. A.; Teicher, B. A.; Frei, E. III. Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro. Cancer Chemother. Pharmacol. 25:32-36; 1989.
27. 27. Carapella, C. M.; Iandolo, B.; Delle Chiaie, S.; Riccio, A. Lonidamine in primary malignant brain tumors. Oncology 41 Suppl. 1:82-85; 1984.
28. 28. Zupi, G.; Greco, C.; Laudonio, N.; Benassi, M.; Silvestrini, B.; Caputo, A. In vitro and in vivo potentiation of the antitumor effect of adriamycin. Anticancer Res. 6:1245-1250; 1986.
29. 29. Kim, J. H.; Alfieri, A. A.; Kim, S. H.; Young, C. W. Potentiation of radiation effects of two murine tumors by lonidamine. Cancer Res. 46:1120-1123; 1986.
30. 30. Raaphorst, G. P.; Feeley, M. M.; Danjoux, C. E.; Martin, L.; Mariun, J.; De Sanctis, A. J. The effect of lonidamine (LND) on radiation and thermal responses of human and rodent cell lines. Int. J. Radiat. Oncol. Biol. Phys. 20: 509-515; 1991.
31. 31. Raaphorst, G. P.; Feeley, M. M.; Martin, L.; Danjoux, C. E.; Maroun, J.; De Santis, A. J.; Ko, D. Enhancement of sensitivity to hyperthermia by lonidamine in human cancer cells. Int. J. Hyperthermia 7:763-772; 1991.
32. 32. Cividalli, A.; Gentile, F. P.; Alonzi, A.; Benassi, M.; Mauro, F.; Floridi, A. In vivo control of tumor growth by lonidamine and radiations, influence of the timing and sequence of drug: administration and irradiation treatment. Int. J. Oncol. 1:561-565; 1992.
33. 33. Cividalli, A.; Gentile, F. P.; Begnozzi, L.; Chiatti, L.; Benassi, M.; Floridi, A. In vivo control of tumor growth with the association of lonidamine with radiation and/or hyperthermia. Int. J. Oncol. 2:791-795; 1993.
34. 34. Floridi, A.; Gentile, F. P.; Bruno, T.; Delpino, A.; Iacobini, C.; Paggi, M. G.; Castiglione, S.; Benassi, M. Thermal behavior of a human glioma cell line and its response to combinations of hyperthermia and lonidamine. Oncol. Res. 5:1-10; 1993.
35. 35. Cavaliere, R.; Di Filippo, F.; Varanese, A.; Carlini, S.; Calabrò, A.; Aloe, L.; Piarulli, L. Lonidamine and hyperthermia: clinical experience in melanoma. Oncology 41 Suppl 1:116-120; 1984.
36. 36. Calabresi, F.; Di Lauro, L.; Marolla, P.; Gallo Curcio, C.; Paoletti, G.; Calabrò, A.; Giannarelli, D.; Ballatore, P.; Foggi, C.M.; Di Palma, M.; Stolfi, R.; Cortese, R. Fluorouracil, doxorubicin, and cyclophosphamide vs. fluorouracil, doxorubicin, and cyclophosphamide plus lonidamine for the treatment of advanced breast cancer. A multicentric randomized clinical study. Semin. Oncol. 18 (2 Suppl 4): 66-72; 1991.
37. 37. Possinger, K.; Wagner, H.; Kovacs, S.; Flath, B.; Classen, S.; Wilmanns, W. Lonidamine in high-risk breast cancer patients. Semin. Oncol. 18 (2 Suppl 4): 58-61; 1991.
38. 38. Citro, G.; Cucco, C.; Verdina, A.; Zupi, G. Reversal of adriamycin resistance by lonidamine in a human breast cancer cell line. Br. J. Cancer 64:534-536; 1991.
39. 39. Kaplan, O.; Navon, G.; Lyon, R. C.; Faustino, P. J.; Straka, E. J.; Cohen, J. S. Effect of 2-deoxyglucose on drug-sensitive and drug-resistant human breast cancer cells: toxicity and magnetic resonance spectroscopy studies of metabolism. Cancer Res. 50:544-551; 1990.
40. 40. Scott, F.; Fracastoro, A. P.; Taft, E. B. Studies in histochemistry. Determination of nucleic acids in microgram amounts of tissue. J. Histochem. Cytochem. 4:1-10; 1956.
41. 41. Hohorst, H. J. Determination with lactic dehydrogenase and DPN. In Bergmeyer, H. U., ed. Methods of enzymatic analysis. New York: Academic Press; 1965:pp. 266-270.
42. 3H compounds. Anal. Biochem. 7: 207-214; 1964.
43. 43. Katz, J. Landau, B. R.; Bartsch, G. E. The pentose cycle, triose phosphate isomerization, and lipogenesis in rat adipose tissue. J. Biol. Chem. 241:727-740; 1966.
44. 14C and estimation of transaldolase, transketolase, the contribution of the pentose cycle and ribose phosphate synthesis. Biochemistry 6:2227-2247; 1967.
45. 45. Floridi, A.; Barbieri, R.; Pulselli, R.; Fanciulli, M.; Arcuri, E. Effect of the local anesthetic bupivacaine on the energy metabolism of Ehrlich ascites tumor cells. Oncol. Res. 6:593-601; 1994.
46. 46. Parry, D.; Pedersen, P. L. Intracellular localization and properties of particulate hexokinase in the Novikoff ascites tumor. J. Biol. Chem. 258:10904-10912; 1983.
47. 47. Kaushal, V.; Barnes, L. D. Effect of zwitterionic buffers on measurement of small masses of protein with bicinchoninic acid. Anal. Biochem. 157:291-294; 1986.
48. 48. Stocchi, V.; Cucchiarini, M.; Magnani, L.; Chiarantini, P.; Crescentini, G. Simultaneous extraction and reverse-phase high-performance liquid chromatographic determination of adenine and pyridine nucleotides in human red blood cells. Anal. Biochem. 146:118-124; 1985.
49. 49. Arora, K. K.; Pedersen, P. L. Functional significance of mitochondrial bound hexokinase in tumor cell metabolism. Evidence for preferential phosphorylation of glucose by intramitochondrially generated ATP. J. Biol. Chem. 263:17422-17428; 1988.
50. 13C nuclear magnetic resonance studies. Cancer Res. 55:2814-2821; 1995.
51. 51. Arancia, G.; Malorni, W.; Crateri Trovalusci, P.; Isacchi, G.; Giannella, G.; De Martino, C. Differential effect of lonidamine on the plasma membrane ultrastructure of normal and leukemic human lymphocytes. Exp. Mol. Pathol. 48:37-47; 1988.
52. 52. Vivi, A.; Tassini, M.; Navon, G.; Kaplan, O. Comparison of action of anti-neoplastic drug lonidamine between drug sensitive and multidrug resistant MCF-7 human breast cancer cells. Proceedings of the Third International Congress of the Magnetic Resonance Society, Nice, France, August 1995:pp. 1699.
53. 53. Paggi, M. G.; Caputo, A. Clinical significance of a rearranged hexokinase isozymes expression in neoplastic phentype: the astrocytoma model. In: Cimino, F.; Birkmayer, G. D.; Klavins, J. V.; Plimentel, E.; Salvatore, F., eds. Human Tumor Markers. Berlin: Walter de Gruyter & Co; 1987:pp. 869-881.
54. 54. Santini, M. T.; Indovina, P. L.; Simmons, J. R.; Scott, W. P. Human erythrocyte insulin receptor downregulation is accompanied by a transient decrease in membrane order. Biochem. Biophys. Acta 1054:333-336; 1990.
55. 55. De Peyster, A.; Hyslop, P. A.; Kuhn, C. E.; Sauerheber, R. D. Membrane structural/functional perturbations induced by gossypol. Effects on membrane order, liposome permeability, and insulin-sensitive hexose transport. Biochem. Pharmacol. 35: 3293-3300; 1986.
56. 56. Oudard, S.; Poirson, F.; Miccoli, L.; Bourgeois, Y.; Vassault, A.; Poisson, M.; Magdelenat, H.; Dutrillaux, B.; Poupon, M. F. Mitochondria-bound hexokinase as target for therapy of malignant gliomas. Int. J. Cancer 62:216-222; 1995.